The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

A team of neuroscientists in Australia has found that restoring copper levels in the brain dramatically reduced Parkinson-like damage in mice. The approach restored a protein’s function, and the same ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

In its last fund raising round last year, Insightec’s valuation was at just $515 million, as emerges from the financials of listed company Elbit Medical, which holds 2% of Insightec.

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...